Adherence and Intensity of Lipid-Lowering Therapy Influences CV Risk
MONDAY, Dec. 17, 2018 -- Adherent patients receiving high-intensity statin and/or ezetimibe therapy have the lowest cardiovascular risk, according to a study published online Dec. 7 in JAMA Network Open.
Kamlesh Khunti, M.D., from the University of...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Cardiology | Cardiovascular | Cholesterol | Heart | Pharmaceuticals | Statin Therapy | Study | Vytorin | Zetia